{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:17:09Z","timestamp":1788455829330,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40487-025-00372-0","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:38:42Z","timestamp":1757000322000},"page":"1041-1054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05060016","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Myung-Ju","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadoaki","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Youn","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Lu","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujoy","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraoki","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"11","key":"372_CR1","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/s1470-2045(23)00444-8","volume":"24","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Vaccarella S, Morgan E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023;24(11):1206\u201318. https:\/\/doi.org\/10.1016\/s1470-2045(23)00444-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"372_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1): 3. https:\/\/doi.org\/10.1038\/s41572-020-00235-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"372_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30539-8.","journal-title":"Lancet Oncol"},{"issue":"23","key":"372_CR4","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"issue":"6","key":"372_CR5","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s10147-021-01899-8","volume":"26","author":"K Hotta","year":"2021","unstructured":"Hotta K, Nishio M, Saito H, et al. First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. Int J Clin Oncol. 2021;26(6):1073\u201382. https:\/\/doi.org\/10.1007\/s10147-021-01899-8.","journal-title":"Int J Clin Oncol"},{"issue":"suppl 9","key":"372_CR6","doi-asserted-by":"publisher","first-page":"ix197","DOI":"10.1093\/annonc\/mdz446.014","volume":"30","author":"M Nishio","year":"2019","unstructured":"Nishio M, Ji JH, Hotta K, et al. Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia. Ann Oncol. 2019;30(suppl 9):ix197\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz446.014.","journal-title":"Ann Oncol"},{"issue":"6","key":"372_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cllc.2019.07.005","volume":"20","author":"M Nishio","year":"2019","unstructured":"Nishio M, Sugawara S, Atagi S, et al. Subgroup analysis of Japanese patients in a phase III study of atezolizumab in extensive-stage small-cell lung cancer (IMpower133). Clin Lung Cancer. 2019;20(6):469-476e1. https:\/\/doi.org\/10.1016\/j.cllc.2019.07.005.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"372_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","volume":"16","author":"CM Rudin","year":"2023","unstructured":"Rudin CM, Reck M, Johnson ML, et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16(1):66. https:\/\/doi.org\/10.1186\/s13045-023-01464-y.","journal-title":"J Hematol Oncol"},{"issue":"22","key":"372_CR9","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2307980.","journal-title":"N Engl J Med"},{"issue":"5","key":"372_CR10","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","volume":"27","author":"MJ Giffin","year":"2021","unstructured":"Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2845.","journal-title":"Clin Cancer Res"},{"key":"372_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.lungcan.2020.07.026","volume":"147","author":"F Rojo","year":"2020","unstructured":"Rojo F, Corassa M, Mavroudis D, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237\u201343. https:\/\/doi.org\/10.1016\/j.lungcan.2020.07.026.","journal-title":"Lung Cancer"},{"key":"372_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.057","author":"J Sands","year":"2024","unstructured":"Sands J, Cho BC, Ahn MJ. OA10.03 tarlatamab sustained clinical benefit and safety in previously treated SCLC: DeLLphi-301 phase 2 extended follow-up. J Thorac Oncol. 2024. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.057.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"372_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"372_CR14","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","volume":"15","author":"HC Chung","year":"2020","unstructured":"Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15(4):618\u201327. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.109.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"372_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","volume":"14","author":"N Ready","year":"2019","unstructured":"Ready N, Farago AF, de Braud F, et al. Third-line nivolumab monotherapy in recurrent SCLC: checkmate 032. J Thorac Oncol. 2019;14(2):237\u201344. https:\/\/doi.org\/10.1016\/j.jtho.2018.10.003.","journal-title":"J Thorac Oncol"},{"key":"372_CR16","unstructured":"Thailand Food and Drug Administration. https:\/\/en.fda.moph.go.th\/\/. Accessed 15 May 2024."},{"key":"372_CR17","unstructured":"Taiwan Food and Drug Administration. https:\/\/www.fda.gov.tw\/eng\/\/. Accessed 15 May 2024."},{"key":"372_CR18","unstructured":"National Pharmaceutical Regulatory Agency, Ministry of Health Malaysia. Accessed 15 May 2024, https:\/\/www.npra.gov.my\/index.php\/en\/"},{"key":"372_CR19","unstructured":"National Medical Products Administration China. https:\/\/english.nmpa.gov.cn\/drugs.html\/. Accessed 15 May 2024."},{"key":"372_CR20","unstructured":"Ministry of Health Labour and Welfare of Japan. https:\/\/www.mhlw.go.jp\/english\/\/. Accessed 15 May 2024."},{"key":"372_CR21","unstructured":"Ministry of Food and Drug Safety Korea. https:\/\/www.mfds.go.kr\/eng\/index.do\/. Accessed 15 May 2024."},{"key":"372_CR22","unstructured":"Health Sciences Authority Singapore. Accessed 15 May 2024, https:\/\/www.hsa.gov.sg\/. Accessed 15 May 2024."},{"key":"372_CR23","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Small Cell Lung Cancer. Version 2.2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1462. Accessed 17 Oct 2024."},{"key":"372_CR24","unstructured":"US Food and Drug Administration. https:\/\/www.fda.gov\/. Accessed 15 May 2024."},{"key":"372_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02245","author":"GP Kalemkerian","year":"2024","unstructured":"Kalemkerian GP, Khurshid H, Ismaila N, Systemic Therapy for Small Cell Lung Cancer Guideline Expert P. Systemic therapy for small cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO-24-02245.","journal-title":"J Clin Oncol"},{"key":"372_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.546672","volume":"11","author":"JS Lee","year":"2021","unstructured":"Lee JS, Kim S, Sung SY, et al. Treatment outcomes of 9,994 patients with extensive-disease small-cell lung cancer from a retrospective nationwide population-based cohort in the Korean HIRA database. Front Oncol. 2021;11: 546672. https:\/\/doi.org\/10.3389\/fonc.2021.546672.","journal-title":"Front Oncol"},{"issue":"1","key":"372_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12885-021-08082-2","volume":"21","author":"SR Kim","year":"2021","unstructured":"Kim SR, Hong JH, Sung SY, et al. Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study. BMC Cancer. 2021;21(1):340. https:\/\/doi.org\/10.1186\/s12885-021-08082-2.","journal-title":"BMC Cancer"},{"issue":"8","key":"372_CR28","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/1759-7714.13412","volume":"11","author":"D Li","year":"2020","unstructured":"Li D, Xu X, Liu J, et al. Small cell lung cancer (SCLC) incidence and trends vary by gender, geography, age, and subcategory based on population and hospital cancer registries in Hebei, China (2008\u20132017). Thorac Cancer. 2020;11(8):2087\u201393. https:\/\/doi.org\/10.1111\/1759-7714.13412.","journal-title":"Thorac Cancer"},{"issue":"3","key":"372_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.47102\/annals-acadmedsg.V36N3p181","volume":"36","author":"CK Toh","year":"2007","unstructured":"Toh CK, Hee SW, Lim WT, et al. Survival of small-cell lung cancer and its determinants of outcome in Singapore. Ann Acad Med Singap. 2007;36(3):181\u20138.","journal-title":"Ann Acad Med Singap"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00372-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00372-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00372-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:14:49Z","timestamp":1764087289000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00372-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["372"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00372-0","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Myung-Ju Ahn declares honoraria from AstraZeneca, Lilly, MSD, Takeda, Amgen, Merck Serono, YUHAN and Daiichi Sankyo\/AstraZeneca; consulting or advisory role from AstraZeneca, Lilly, MSD, TAKEDA, Alpha Pharmaceutical, Amgen, Merck Serono, Pfizer, YUHAN, Arcus Ventures and Daiichi Sankyo\/AstraZeneca; and research funding from YUHAN. Byoung Chul Cho declares research funding from MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, GIInnovation, GI-Cell, Abion, AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Champions Oncology, CJ Bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Janssen, Lilly, MSD, Novartis, Nuvalent, Oncternal, Ono, Regeneron, Dong-A ST, BridgeBio Therapeutics, YUHAN, ImmuneOncia, Illumina, Kanaph Therapeutics, Therapex, JINTSbio, Hanmi, CHA Bundang Medical Center and Vertical Bio AG. Kadoaki Ohashi declares honoraria from Amgen Inc., Boehringer Ingelheim Japan, Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan, Bristol Myers Squibb, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Taiho Pharmaceutical Co., Ltd., MSD K.K. and Novartis Japan; and research funding from Amgen, BeiGene, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo, Taiho Pharmaceutical Co., Ltd. and Eli Lilly Japan. Hiroki Izumi declares speaker fees from Takeda, Merck, Ono Pharmaceutical, MSD, Chugai, and Bristol-Myers Squibb Japan; research funding from AbbVie, AstraZeneca, Amgen, Takeda, Eisai and Ono Pharmaceutical; and advisory fees from Amgen. Jong-Seok Lee declares no conflicts of interest. Ji-Youn Han declares consulting fees from AstraZeneca, Amgen, AbbVie, Daiichi Sankyo, LG Chem, Oncovix, Dae Woong, Novartis, Lantern, BMS, Janssen, Merck, Takeda, Pfizer and Roche; honoraria from AstraZeneca, Janssen, Takeda, Merck, Novartis, Pfizer, YUHAN, Takeda and Roche; expert testimony from AstraZeneca; participation in data safety monitoring or on the advisory board for Janssen and AstraZeneca. Chi-Lu Chiang declares honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Pfizer and Roche. Shuang Huang, Ali Hamidi, Sujoy Mukherjee, and Krista Lin Xu declare employment by and stock ownership in Amgen Inc. Hiraoki Akamatsu declares honoraria from Amgen Inc., AstraZeneca K.K., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Eli Lilly Japan K.K., MSD K.K., Nippon Kayaku Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Taiho Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co. Ltd; advisory role for Amgen Inc., GSK, Janssen Pharmaceutical K.K. and Sandoz; and research funding from Amgen Inc., Chugai Pharmaceutical Co., Ltd., Novartis and MSD K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}},{"value":"DeLLphi-301 was conducted in accordance with the International Council for Harmonisation Good Clinical Practice guidelines and the principles of the Declaration of Helsinki of 1964 and its later amendments. The protocol and amendments were approved by the institutional review board or ethics committee at each participating site (see supplementary appendix for details) and by the regulatory authorities in the participating countries. All patients provided written informed consent. A data review team external to the trial team provided oversight of safety throughout the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}